Overview

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Status:
Recruiting

Trial end date:
2024-07-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Joshua M Hare

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)